Moreover, most patients with KCNQ2 encephalopathy carry a heterozygous mutation; thus, the pharmacological responses in the condition when mutation co-expressed with KCNQ2 WT and KCNQ3 (1:1:2 ratio) may better represent the therapy response. Here, KCNQ2 is linked to Encephalopathy.